ABOUT US ALLERGIES PATIENTS SCIENCE NEWS CENTER CAREERS Find your location About us At a Glance Ambition Our ambition Ambition Key facts and figures ABOUT US OUR AMBITION Becoming the world's leading allergen immunotherapy company, by: With a history of innovation, the company is at the origin of a new generation of allergy immunotherapy treatments. Upon its creation, Stallergenes Greer brought an essential contribution to allergy therapies at a time when symptomatic treatments were the gold standard. These efforts have considerably strengthened the level of evidence supporting allergy immunotherapy. Learn more about our history Realising the potential of precision medicine combined with personalised healthcare to improve the quality of life of people with allergies With precision medicine, we identify the mechanisms of allergic response to develop diagnostic tools and AIT treatments Our ambition is to deliver unparalleled personalised patient care through our extensive product portfolio, including all administration routes We continue to develop treatment solutions which can be adjusted to meet patient-specific profiles and needs Changing the course of allergic disease through the largest portfolio of best-in class allergy AIT treatments We focus on delivering state-of-the-art quality products We deepen our knowledge of AIT and meet modern methodological standards for proving efficacy and safety Nurturing scientific innovation and collaborating for long-term growth, creating value for our stakeholders We empower clinicians to make therapeutic decisions based on patients’ needs due to our broad AIT product portfolio We strive to offer patients unparalleled support We contribute to our society, where climate change and increasing pollution will result in half of people having allergies by 2050 Being a trusted partner in allergy management and making a lasting and positive contribution to society We unlock the potential of every colleague with lifelong learning and development We build on our pioneering heritage to embed innovative thinking into our ways of working, benefiting our people, patients and physicians We improve patient experience by collaborating with partners in technological innovation, molecular research and developments in allergy biomarkers and drug delivery methodologies Our strategy > At Stallergenes Greer, we operate to sustain growth and create value for society as a whole. The company’s strategy is based on three pillars: precision medicine for better patient care, investing in our people, a high-performance agile organisation. Learn more about our strategy © 2021 Stallergenes Greer Site Map Terms & Conditions Modern Slavery Act Statement Contact Cookie Policy Personal Data Protection Policy Cookies Reject and continue STALLERGENES GREER uses technical cookies essential for the functioning of the site as well as audience measurement cookies. You can accept audience measurement cookies by clicking on “Accept” or reject them by clicking on “Reject and continue”. You can change your mind at any time by clicking on “Cookies Management” and manage your preferences by clicking on “Set your preferences”. For more information, please read our Cookie Policy Set your preferences Accept